Posted: 27 July 2023 A unique drug delivery platform developed by Monash University researchers in partnership with PureTech Health plc (Nasdaq: PRTC, LSE: PRTC), has reached another exciting milestone, with the initiation of a Phase 2a clinical trial of LYT-300…
Posted: 27 June 2023 Avecho Biotechnology Limited (ASX:AVE, “Avecho”, or “the Company”) has today announced it has passed a crucial two–year stability point milestone for its TPM®–enhanced cannabidiol (“CBD”) soft–gel capsule. Cannabinoids are susceptible to degradation from a…
Posted: 21 June 2023 Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to report that the MagSense® HER2 imaging agent Phase 1 study (IBI10103) has achieved its enrolment…
Posted: 21 June 2023 Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announced the grant of a new patent (number 11,680,104) by the United States Patent Office.…
Posted: 21 June 2023 Transformative cancer diagnostic technology, Rhythm Biosciences Ltd is pleased to provide an update regarding the technical feasibility pipeline expansion initiatives/opportunities. As previously announced, the Company has identified several other critical cancers where it can…
Posted: 19 June 2023 Vaccines are essential to global public health — available to prevent more than 20 diseases, vaccines avert 3.5 to 5 million deaths each year and combat emerging infectious diseases and the spread of microbial…
Posted: 19 June 2023 Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) to add positive data from the Phase 3 VALOR-HCM study to the U.S.…
Posted: 19 June 2023 A pioneering radiotherapy treatment developed at Peter Mac is emerging as a new treatment option for cancer that has spread to the lungs, following exciting results in a recent study. Long-term survival data is…
Posted: 19 June 2023 Telix today announces that the first patient has been dosed in a Phase II study of the Company’s carbonic anhydrase- (CAIX)-targeting PET/CT[1] imaging agent TLX250-CDx (89Zr-DFO-girentuximab), exploring this potential target across a broad range of…
Posted: 15 June 2023 Melbourne researchers have used heart and lung stem cells infected with the virus that causes COVID-19 to better understand how the disease impacts different organs, paving the way for more targeted treatments. The research,…
Posted: 15 June 2023 Telix Pharmaceuticals has topped the inaugural Financial Review Fast Global list, with international revenue growth at the Melbourne-based, cancer-fighting biotech soaring off the back of a drug approval in the US. The Fast Global…
Posted: 13 June 2023 Telix today welcomes Willy Borsus, Vice-President of Wallonia, Minister of Economy, Research and Innovation, Digital, Agriculture, Urban Planning and Regional Planning to officially open Telix Manufacturing Solutions, the Company’s radiopharmaceutical production facility located in…